- ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
- ACELYRIN, INC. Announces Leadership Transition
- ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
- ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
- ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
- ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
- ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
- ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
- ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
- ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
More ▼
Key statistics
As of last trade ACELYRIN Inc (SLRN:NSQ) traded at 4.33, 4.47% above its 52-week low of 4.14, set on Apr 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.51 |
---|---|
High | 4.51 |
Low | 4.32 |
Bid | 4.32 |
Offer | 4.33 |
Previous close | 4.52 |
Average volume | 661.66k |
---|---|
Shares outstanding | 99.03m |
Free float | 84.30m |
P/E (TTM) | -- |
Market cap | 447.60m USD |
EPS (TTM) | -2.59 USD |
Data delayed at least 15 minutes, as of May 23 2024 17:44 BST.
More ▼